|
Eighth International Congress on Drug Therapy in HIV InfectionGlasgow, UK - 12-16 November 2006 |
Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.3
L K Bansi, A A Benzie, C A Sabin, A N Phillips
Royal Free & University College Medical School, London, UK; St Marys Hospital, London, UK
PURPOSE OF THE STUDY: Recent results from the UK CHIC Study indicate that rates of viral rebound decrease with increasing duration of viral suppression, regardless of the number of previous regimens failed. We have expanded these analyses to determine whether previous episodes of treatment interruption are associated with a raised risk of viral rebound, after controlling for the above mentioned effects.
METHODS: All patients who achieved a viral load of ≤50 cps/mL for the first time while receiving HAART were followed until viral rebound (2 consecutive viral loads of >400 cps/mL). Treatment interruptions were defined as discontinuation of all treatment for at least 2 weeks at any time after having started HAART. Poisson regression was used to calculate relative rates of viral rebound.
SUMMARY OF RESULTS: 1566/10288 (15.2%) patients had at least 1 treatment interruption before their first episode of viral suppression. Of these, 33.4% interrupted an NNRTI regimen, (70.2% of whom restarted the same regimen), 45.2% interrupted a PI regimen (44.1% restarted the same regimen) and 15.1% interrupted a nucleoside only regimen (40.0% restarted the same regimen). Median number of interruptions per patient was 1 (IQR: 1,1), median length per interruption was 141 (61,334) days. In a Poisson regression model, in which patients were eligible to have up to 5 episodes of viral suppression, neither total duration of treatment interruption nor previously having interrupted treatment, were significantly associated with viral rebound (Interrupted vs. not interrupted RR=0.93 CI:0.82,1.07).
CONCLUSIONS: Previous episodes of treatment interruptions do not appear to be associated with viral rebound. Analyses are underway to determine whether the type of regimen interrupted and restarted has impact on viral rebound.
Plenary Session: Oral Papers
2006-11-12
PL8.3
Copyright © 2006 - Thomson ACUMED® All rights reserved. Thomson ACUMED® is an intelligent and innovative medical marketing and communications agency – a new division of The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, located in Tytherington, UK.
Reproduction of this abstract (other than one copy for personal reference) must be cleared through the authors.
This information is designed to support, not replace, the relationship that exists between you and your doctor. ©1980, 2006. AEGiS.